Not logged in Share Save
Share Save
Share Save
Share Save
Share Save
Share Save
Share Save
Share Save
PH009-1, a highly potent, selective and brain-penetrable fourth-generation EGFRTKI that overcome classic and resistant EGFR mutations in NSCLC Gao, Feng; Wang, Jing; Liu, Bin; Wu, Yongyong; Jing, Liandong; Zhang, Pengzhi; Gao, Yu; Li, Zhizhong; Guo, Yongqi Share Save
PH027-1, a potent and selective small-molecule WRN inhibitor that targets MSI-H tumors Gao, Feng; Liu, Bin; Jing, Liandong; Wang, Jing; Wu, Yongyong; Wan, Jun; Zhang, Pengzhi; Gao, Yu; Li, Zhizhong; Guo, Yongqi Share Save
Discovery of YK-029A, a novel mutant EGFR inhibitor targeting both T790 M and exon 20 insertion mutations, as a treatment for NSCLC Liu, Bin; Gao, Feng; Zhao, Hui; Yuan, Shuai; Peng, Xingzhe; Zhang, Pengzhi; Wang, Jing; Zhang, Tongmei; Duan, Maosheng; Guo, Yongqi Share Save
PH020-803: an MTA-cooperative and brain-penetrable PRMT5 inhibitor that selectively targets MTAP-deleted tumors Gao, Feng; Liu, Bin; Jing, Liandong; Wu, Yongyong; Zhang, Pengzhi; Yuan, Shuai; Zhao, Hui; Gao, Yu; Li, Zhizhong; Wang, Xiaofan; Guo, Yongqi Share Save
PH009-1, a highly potent and selective fourth-generation EGFR-TKI overcoming EGFR common mutations and T790M/C797S-mediated resistance in NSCLC Gao, Feng; Liu, Bin; Wu, YongYong; Jing, Liandong; Zhang, Pengzhi; Wang, Jing; Yuan, Shuai; Zhao, Hui; Gao, Yu; Li, Zhizhong; Wang, Xiaofan; Guo, Yongqi Share Save
Share Save
Share Save
Share Save
Share Save
Share Save
Share Save
Share Save
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Not logged in.png){kind=icon}